Joint Advisory Committee Will Grapple With Risk-Benefit Profile Of Tysabri For Crohn’s
This article was originally published in The Pink Sheet Daily
Executive Summary
Safety concerns, including the risk of PML, are still relevant considerations, briefing documents state.
You may also be interested in...
Biogen Idec/Elan Plan To Appeal Negative CHMP Opinion Of Tysabri For Crohn’s
Committee also issues positive opinions on Novartis’ type 2 diabetes therapy Galvus, Pfizer’s oral HIV treatment Celsentri and GSK’s cervical cancer vaccine Cervarix.
Biogen Idec/Elan Submit Tysabri sBLA For Crohn’s Disease
Submission includes labeling and risk management plan to address increased risk of progressive multifocal leukoencephalopathy.
Tysabri Re-Launches In U.S. Through Single Distributor
Biogen Idec/Elan's multiple sclerosis therapy Tysabri is available in the U.S. through a single distributor: AmerisourceBergen Specialty Group division ICS